National Cancer Institute Initiates Studies On ImmuneRegen BioSciences’ Vaccine Adjuvant Candidate ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), announced the execution of an agreement with the National Institute of Health (NIH) / National Cancer Institute (NCI) to commence studies utilizing ImmuneRegen’s Homspera. Under the agreement, the NIH will perform exploratory studies on Homspera relating to mucosal immunity that might lead to … Read more on Medical News Today